A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Key claim: This open-label study evaluates whether rusfertide can maintain hematocrit control and reduce phlebotomy need in Japanese adults with polycythemia vera over up to 244 weeks.
Abstract
Polycythemia vera (PV) is a rare blood cancer in which the body makes too many red blood cells. This can make the blood thicker and may increase the risk of serious health problems such as blood clots. Many people with PV need regular phlebotomy, which is a procedure to remove blood, to help keep their hematocrit level under control. Hematocrit is the proportion of red blood cells in the blood.
The main aim of this study is to evaluate whether rusfertide helps Japanese participants with PV keep their hematocrit under control and avoid the need for phlebotomy. All participants in this study will receive rusfertide. This study is open-label, which means both the participants and the study team will know what treatment is being given.
Participants will be followed for up to about 244 weeks, including a screening period, a 52-week initial treatment period, a long-term extension period, and a 4-week safety follow-up period.
Why this matters
Rusfertide joins sapablursen and DISC-3405 as hepcidin/iron-axis modulators being tested as phlebotomy-sparing, non-cytoreductive therapy specific to PV’s erythrocytosis biology. Extending evaluation into a Japanese cohort over a 244-week horizon adds geographic/ethnic generalizability and long-term durability evidence to a mechanism class that is rapidly maturing within the PV pipeline, paralleling the Japanese ropeginterferon dose-escalation work already on this page.